170 related articles for article (PubMed ID: 36127853)
1. The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases.
Houvenaeghel G; de Nonneville A; Chopin N; Classe JM; Mazouni C; Chauvet MP; Reyal F; Tunon de Lara C; Jouve E; Rouzier R; Daraï E; Gimbergues P; Coutant C; Azuar AS; Villet R; Crochet P; Rua S; Bannier M; Cohen M; Boher JM
Cancer Med; 2023 Feb; 12(4):4023-4032. PubMed ID: 36127853
[TBL] [Abstract][Full Text] [Related]
2. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
3. Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
Houvenaeghel G; Cohen M; Raro P; De Troyer J; de Lara CT; Gimbergues P; Gauthier T; Faure-Virelizier C; Vaini-Cowen V; Lantheaume S; Regis C; Darai E; Ceccato V; D'Halluin G; Del Piano F; Villet R; Jouve E; Beedassy B; Theret P; Gabelle P; Zinzindohoue C; Opinel P; Marsollier-Ferrer C; Dhainaut-Speyer C; Colombo PE; Lambaudie E; Tallet A; Boher JM;
BMC Cancer; 2018 Nov; 18(1):1153. PubMed ID: 30463611
[TBL] [Abstract][Full Text] [Related]
4. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
[TBL] [Abstract][Full Text] [Related]
5. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
[TBL] [Abstract][Full Text] [Related]
6. Inequalities in the omission of axillary dissection in sentinel lymph node positive patients in the Netherlands: Innovative hospitals are early adopters of a de-escalating approach.
van Steenhoven JEC; van Maaren MC; Verreck EEF; Schipper RJ; Nieuwenhuijzen GAP; Kuijer A; Siesling S; van Dalen T
Int J Cancer; 2023 Apr; 152(7):1378-1387. PubMed ID: 36522834
[TBL] [Abstract][Full Text] [Related]
7. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
8. Comparing Observation, Axillary Radiotherapy, and Completion Axillary Lymph Node Dissection for Management of Axilla in Breast Cancer in Patients with Positive Sentinel Nodes: A Systematic Review.
Castelo M; Hu SY; Dossa F; Acuna SA; Scheer AS
Ann Surg Oncol; 2020 Aug; 27(8):2664-2676. PubMed ID: 32020394
[TBL] [Abstract][Full Text] [Related]
9. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
Riedel F; Heil J; Feißt M; Rezai M; Moderow M; Sohn C; Schütz F; Golatta M; Hennigs A
Breast Cancer Res Treat; 2019 Sep; 177(2):457-467. PubMed ID: 31236814
[TBL] [Abstract][Full Text] [Related]
10. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
de Boniface J; Filtenborg Tvedskov T; Rydén L; Szulkin R; Reimer T; Kühn T; Kontos M; Gentilini OD; Olofsson Bagge R; Sund M; Lundstedt D; Appelgren M; Ahlgren J; Norenstedt S; Celebioglu F; Sackey H; Scheel Andersen I; Hoyer U; Nyman PF; Vikhe Patil E; Wieslander E; Dahl Nissen H; Alkner S; Andersson Y; Offersen BV; Bergkvist L; Frisell J; Christiansen P; ;
N Engl J Med; 2024 Apr; 390(13):1163-1175. PubMed ID: 38598571
[TBL] [Abstract][Full Text] [Related]
11. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial.
Andersson Y; Bergkvist L; Frisell J; de Boniface J
Br J Surg; 2021 Sep; 108(9):1105-1111. PubMed ID: 34010418
[TBL] [Abstract][Full Text] [Related]
12. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
Poodt IGM; Spronk PER; Vugts G; van Dalen T; Peeters MTFDV; Rots ML; Kuijer A; Nieuwenhuijzen GAP; Schipper RJ
Ann Surg; 2018 Dec; 268(6):1084-1090. PubMed ID: 28742702
[TBL] [Abstract][Full Text] [Related]
13. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
Riedel F; Heil J; Feisst M; Moderow M; von Au A; Domschke C; Michel L; Schaefgen B; Golatta M; Hennigs A
Breast Cancer Res Treat; 2020 Nov; 184(2):627-636. PubMed ID: 32816190
[TBL] [Abstract][Full Text] [Related]
14. Women Could Avoid Axillary Lymph Node Dissection by Choosing Breast-Conserving Therapy Instead of Mastectomy.
Vane MLG; Hunter-Squires J; Kim S; Smidt ML; Giuliano AE
Ann Surg Oncol; 2021 May; 28(5):2522-2528. PubMed ID: 33586070
[TBL] [Abstract][Full Text] [Related]
15. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
Galimberti V; Cole BF; Viale G; Veronesi P; Vicini E; Intra M; Mazzarol G; Massarut S; Zgajnar J; Taffurelli M; Littlejohn D; Knauer M; Tondini C; Di Leo A; Colleoni M; Regan MM; Coates AS; Gelber RD; Goldhirsch A;
Lancet Oncol; 2018 Oct; 19(10):1385-1393. PubMed ID: 30196031
[TBL] [Abstract][Full Text] [Related]
16. Sentinel node positive breast cancer patients who do not undergo axillary dissection: are they different?
Zakaria S; Pantvaidya G; Reynolds CA; Grant CS; Sterioff S; Donohue JH; Farley DR; Hoskin TL; Degnim AC
Surgery; 2008 May; 143(5):641-7. PubMed ID: 18436012
[TBL] [Abstract][Full Text] [Related]
17. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes.
Houvenaeghel G; Boher JM; Reyal F; Cohen M; Garbay JR; Classe JM; Rouzier R; Giard S; Faure C; Charitansky H; Tunon de Lara C; Daraï E; Hudry D; Azuar P; Gimbergues P; Villet R; Sfumato P; Lambaudie E
Eur J Cancer; 2016 Nov; 67():106-118. PubMed ID: 27640137
[TBL] [Abstract][Full Text] [Related]
18. Surgeon Bias in the Management of Positive Sentinel Lymph Nodes.
Mathias BJ; Sun J; Sun W; Zhou JM; Fulp WJ; Laronga C; Lee MC; Kiluk JV
Clin Breast Cancer; 2021 Feb; 21(1):74-79. PubMed ID: 32917535
[TBL] [Abstract][Full Text] [Related]
19. Comparing Early-Stage Breast Cancer Patients with Sentinel Lymph Node Metastasis with and without Completion Axillary Lymph Node Dissection: A Systematic Review and Meta-Analysis.
Heiranizadeh N; Rafiei Shahamabadi M; Dehghan HR; Jafari-Nedooshan J; Kargar S; Zare M; Amooei A; Shiryazdi SM; Broomand MA; Moravej MT; Sadri Z
Asian Pac J Cancer Prev; 2022 Aug; 23(8):2561-2571. PubMed ID: 36037108
[TBL] [Abstract][Full Text] [Related]
20. Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases.
Majid S; Rydén L; Manjer J
BMC Cancer; 2019 Jun; 19(1):626. PubMed ID: 31238899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
